CD274 and prostate carcinoma: The U.S. Food and Drug Administration (FDA) approval of the checkpoint inhibitor anti-CTLA4 and the Provenge prostate cancer vaccine has been followed by recent FDA approvals of anti-PD-L1/PD-1 immune checkpoint inhibitors [65–67].